Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

REDWOOD CITY, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in one-on-one meetings with institutional investors at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, taking place September 23-24, 2019, in New York City.